glp 1 suicidal ideation Weight-Loss Drugs Don't Cause Thoughts, FDA Says The risk of depression, anxiety,

Ethics declarations Conflicts of Interest Financial interests: ZM has stock in Novo Nordisk Pharmaceuticals and served as a consultant for Neptune Medical

The pioneering work in the GLP-1 field was carried out in parallel in the United States and Denmark, the historical centers (along with Canada) of insulin pharmacology, and eventually spawned blockbuster drugs like Victoza, Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, and Zepbound that have dominated recent public conversations in science, medicine, and popular culture [1, 2]

But now scientists are raising concerns that are likely to surprise both patients and physicians: possible bone fractures and even vision problems

Mi SciELO Servicios Personalizados Revista Articulo Indicadores Citado por SciELO Accesos Links relacionados Similares en SciELO Compartir Medicina Oral, Patologa Oral y Ciruga Bucal (Internet) versin On-line ISSN 1698-6946 Med

"We made a deliberate strategic pivot within our weight loss specialty, one that we knew would create near-term financial noise to unlock immense potential for the platform to accelerate at scale," Yemi Okupe, chief financial officer at Hims & Hers, told investors during the company's Q1 earnings call on Monday

Switching to semaglutide may help because the single-receptor approach sometimes produces milder GI effects, but the improvement is not guaranteed